Glaucoma is a disease affecting millions of people across the world every year. Medications designed to control or decrease intraocular pressure are the gold standard for treatment and often belong to a class of medications called prostaglandin analogues. These topical agents are well tolerated and alleviate intraocular pressure by inducing the flow of aqueous humor through the interstitial spaces of the ciliary muscle. A novel medication with potential for increased efficacy in intraocular pressure reduction is needed for glaucoma treatment, and evidence is mounting for the new class of nitric oxide-donating prostaglandins to achieve this task. This review aims to present and discuss the evidence pertaining to NCX-470, a nitric oxide-donating prostaglandin.